What Is NAD+ Therapy

NAD+ therapy is the clinical delivery of nicotinamide adenine dinucleotide, a coenzyme found in every living cell, directly into the body through intravenous infusion, subcutaneous injection, or nasal spray. NAD+ is essential for converting nutrients into cellular energy and serves as a substrate for enzymes that repair DNA, regulate gene expression, and manage stress responses. The therapy aims to restore intracellular NAD+ concentrations that diminish with aging, chronic illness, and metabolic dysfunction.

NAD+ sits at the intersection of nearly every major metabolic process in the body. It is required by the mitochondria to produce ATP, the cell's primary energy currency, and it activates sirtuins, a family of proteins involved in genomic stability, inflammation control, and cellular longevity. NAD+ also serves as a substrate for poly(ADP-ribose) polymerases (PARPs), enzymes that repair single-strand DNA breaks. When NAD+ levels fall, all of these processes slow down simultaneously.

Measurable declines in tissue NAD+ have been observed across multiple organ systems with advancing age, and lower NAD+ levels correlate with hallmarks of aging such as mitochondrial dysfunction, increased DNA damage, and chronic low-grade inflammation. This connection has made NAD+ repletion a focal point in longevity science, with the therapeutic question centering on whether restoring youthful NAD+ concentrations can delay or reverse age-related functional decline.

Intravenous NAD+ therapy introduces the intact coenzyme directly into the bloodstream, where it is distributed to tissues without passing through the gastrointestinal tract. Once inside cells, NAD+ participates in two major categories of reactions. In redox metabolism, it cycles between its oxidized form (NAD+) and its reduced form (NADH), shuttling electrons through the mitochondrial electron transport chain to generate ATP. In signaling reactions, it is consumed (not merely cycled) by enzymes like sirtuins and PARPs, meaning the cell must continuously replenish its supply.

Sirtuins, particularly SIRT1 and SIRT3, use NAD+ to remove acetyl groups from proteins, a process that regulates mitochondrial biogenesis, autophagy, and inflammatory gene expression. When NAD+ is abundant, sirtuin activity increases, which in animal models correlates with improved metabolic health and extended lifespan. PARPs consume even larger quantities of NAD+ during DNA repair; under conditions of chronic DNA damage, PARP activity can deplete NAD+ faster than the cell can regenerate it, creating a vicious cycle of repair failure.

The rationale for IV delivery rather than oral precursors (NMN, NR, niacin) is pharmacokinetic: bypassing the gut and liver avoids first-pass metabolism and enzymatic conversion bottlenecks, achieving rapid elevation of circulating NAD+. Whether this translates to meaningfully higher intracellular concentrations in target tissues compared to well-absorbed oral precursors remains an area of active investigation. Some clinics also offer subcutaneous injections or intranasal formulations as lower-cost alternatives with intermediate bioavailability.

A typical NAD+ infusion session begins with a brief intake assessment, including vital signs and a review of current medications. An IV catheter is placed, usually in the forearm, and the NAD+ solution is delivered via slow drip. Most clinics start with a lower dose and slower rate for the first session to gauge tolerance. Patients commonly experience a warm, flushing sensation in the chest and abdomen, and some feel temporary nausea or a sense of pressure. These effects are dose-rate dependent; slowing the infusion usually provides relief within minutes.

Sessions last approximately two to four hours, during which patients can read, work on a laptop, or rest. Some clinics add complementary nutrients (B vitamins, magnesium, amino acids) to the infusion or offer them as a separate drip. Immediately after, most people feel either energized or mildly fatigued; a minority describe a distinct sense of mental clarity. The response tends to become more noticeable after the second or third session in a loading series rather than from a single infusion.

Initial protocols typically involve a loading phase of three to six sessions over one to two weeks, particularly for individuals with significant fatigue or those using the therapy for substance use recovery support. After loading, maintenance schedules vary widely: monthly infusions are common, though some individuals space sessions every six to eight weeks based on symptom response and budget. Lower-dose "booster" infusions of 250 mg can often be completed in under two hours, making them more practical for ongoing use.

Some practitioners combine IV loading with daily oral NAD+ precursors (NMN or NR) to maintain elevated levels between infusions. There are no standardized guidelines for treatment duration; most protocols are empirically driven, guided by subjective response and, when available, lab markers of metabolic function.

NAD+ IV infusions typically range from $500 to $1,500 per session in the United States, with pricing influenced by dose (250 mg versus 500 mg versus 750 mg or higher), geographic location, and the clinic's overhead model. A full loading series of four to six sessions may total $3,000 to $7,500 before any maintenance visits. Subcutaneous injection protocols, where available, tend to cost less per session, often in the $150 to $400 range, because they require less clinical time and supervision.

NAD+ therapy is not covered by most insurance plans, as it is considered elective and lacks FDA approval for a specific indication. Some clinics offer package pricing or membership models that reduce the per-session cost for patients committing to a maintenance schedule. When comparing costs, it is worth noting that high-quality oral NMN or NR supplements, at effective doses, may run $50 to $150 per month, representing a substantially lower cost for a conceptually related (though pharmacokinetically different) approach.

The basic science linking NAD+ to aging is well established. Multiple animal studies, primarily in mice, have demonstrated that boosting NAD+ through genetic or pharmacological means can improve mitochondrial function, enhance DNA repair, reduce inflammation, and extend healthspan metrics such as endurance, insulin sensitivity, and cognitive performance. Some of these studies used NAD+ precursors (NMN, NR) rather than direct NAD+ infusion, so extrapolating results to IV therapy requires caution.

Human evidence for NAD+ therapy specifically (as opposed to oral precursors) is limited. Small open-label studies and case series have reported improvements in fatigue, cognitive function, and quality of life in populations including people with chronic fatigue, substance use disorders, and age-related decline. However, large randomized, placebo-controlled trials of IV NAD+ are absent from the published literature as of the current evidence base. The placebo component is particularly difficult to control for, given the distinctive physical sensations of infusion. Meanwhile, clinical trials of oral precursors like NR have shown that blood NAD+ levels can be raised, but translating that into measurable clinical endpoints such as improved muscle function or reduced cardiovascular risk has produced mixed results so far.

Common side effects during infusion include nausea, flushing, chest pressure, abdominal cramping, and lightheadedness, all of which typically resolve when the drip rate is slowed. Because NAD+ fuels cellular growth and repair broadly, theoretical concerns exist about promoting the metabolism of existing cancer cells, though no clinical data confirm this risk. The therapy is not FDA-approved for any specific indication, and quality control varies between compounding pharmacies that supply the product. Individuals with active malignancies, severe cardiac arrhythmias, or those who are pregnant should discuss the risk profile with a provider experienced in NAD+ administration.